MX2016006125A - Procedimiento, matriz y uso de los mismos. - Google Patents

Procedimiento, matriz y uso de los mismos.

Info

Publication number
MX2016006125A
MX2016006125A MX2016006125A MX2016006125A MX2016006125A MX 2016006125 A MX2016006125 A MX 2016006125A MX 2016006125 A MX2016006125 A MX 2016006125A MX 2016006125 A MX2016006125 A MX 2016006125A MX 2016006125 A MX2016006125 A MX 2016006125A
Authority
MX
Mexico
Prior art keywords
pancreatic cancer
array
determining
individual
test sample
Prior art date
Application number
MX2016006125A
Other languages
English (en)
Spanish (es)
Inventor
Carl Arne Krister Borrebaeck
Christer Lars Bertil Wingren
Original Assignee
Immunovia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovia Ab filed Critical Immunovia Ab
Publication of MX2016006125A publication Critical patent/MX2016006125A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54386—Analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Peptides Or Proteins (AREA)
MX2016006125A 2013-11-11 2014-11-11 Procedimiento, matriz y uso de los mismos. MX2016006125A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1319878.3A GB201319878D0 (en) 2013-11-11 2013-11-11 Method, Array and use thereof
PCT/GB2014/053340 WO2015067969A2 (en) 2013-11-11 2014-11-11 Method, array and use thereof

Publications (1)

Publication Number Publication Date
MX2016006125A true MX2016006125A (es) 2016-08-12

Family

ID=49818441

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016006125A MX2016006125A (es) 2013-11-11 2014-11-11 Procedimiento, matriz y uso de los mismos.

Country Status (12)

Country Link
US (3) US20160252513A1 (enExample)
EP (1) EP3069143B1 (enExample)
JP (1) JP6600637B2 (enExample)
KR (1) KR102240473B1 (enExample)
CN (1) CN105917230B (enExample)
AU (1) AU2014345484B2 (enExample)
BR (1) BR112016010510A2 (enExample)
CA (1) CA2930211A1 (enExample)
ES (1) ES2704888T3 (enExample)
GB (1) GB201319878D0 (enExample)
MX (1) MX2016006125A (enExample)
WO (1) WO2015067969A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008117067A2 (en) 2007-03-27 2008-10-02 Carl Arne Krister Borrebaeck Protein signature/markers for the detection of adenocarcinoma
GB201014837D0 (en) 2010-09-07 2010-10-20 Immunovia Ab Biomarker signatures and uses thereof
GB201103726D0 (en) 2011-03-04 2011-04-20 Immunovia Ab Method, array and use thereof
CN105021825B (zh) * 2015-07-09 2016-08-17 陈勇 一种检测胰腺癌相关多肽dap44的elisa试剂盒
GB201516801D0 (en) 2015-09-22 2015-11-04 Immunovia Ab Method, array and use thereof
GB201608192D0 (en) * 2016-05-10 2016-06-22 Immunovia Ab Method, array and use thereof
GB201609950D0 (en) * 2016-06-07 2016-07-20 Immunovia Ab Biomarkers signatures and uses thereof
GB201609951D0 (en) * 2016-06-07 2016-07-20 Immunovia Ab Biomarkers signatures and uses thereof
EP4053557A1 (en) * 2016-11-24 2022-09-07 Huvet Bio, Inc. Il-29 as a marker for a pancreatic disease
GB201701572D0 (en) 2017-01-31 2017-03-15 Immunovia Ab Methods, arrays and uses thereof
KR102536314B1 (ko) * 2018-05-23 2023-05-25 주식회사 휴벳바이오 질환의 진단용 조성물
US11487739B2 (en) * 2019-02-19 2022-11-01 Nasdaq, Inc. System and methods for data model detection and surveillance
CA3138991A1 (en) * 2019-05-02 2020-11-05 Ligandal, Inc. Methods and compositions for diagnostically-responsive ligand-targeted delivery of therapeutic agents
WO2020235943A1 (ko) * 2019-05-21 2020-11-26 (주)아큐레시스바이오 암의 진단용 조성물
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof
KR102226826B1 (ko) * 2020-08-06 2021-03-11 주식회사 휴벳바이오 버피 코트 시료에 사용하기 위한 췌장암 진단용 조성물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE12586T1 (de) 1980-05-02 1985-04-15 Edward P Davis Beinentlastungsgeraet.
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US5856090A (en) 1994-09-09 1999-01-05 The Scripps Research Institute DNA-methylase linking reaction
GB9703369D0 (en) 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
US6727066B2 (en) * 2000-07-28 2004-04-27 Incyte Corporation Genes expressed in treated human C3A liver cell cultures
CN1659287A (zh) * 2002-04-05 2005-08-24 美国政府健康及人类服务部 诊断肝癌转移或发病可能性及鉴定治疗靶点的方法
JP4679149B2 (ja) * 2002-09-30 2011-04-27 オンコセラピー・サイエンス株式会社 ヒト膵癌に関連する遺伝子およびポリペプチド
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US7217807B2 (en) * 2002-11-26 2007-05-15 Rosetta Genomics Ltd Bioinformatically detectable group of novel HIV regulatory genes and uses thereof
KR20060041205A (ko) * 2003-07-01 2006-05-11 이뮤노메딕스, 인코오포레이티드 양특이성 항체들의 다가 담체들
BR122018073034B1 (pt) * 2004-05-28 2021-10-13 Agensys, Inc Anticorpos e moléculas relacionadas que se ligam à proteínas de psca
US8383357B2 (en) * 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
CA2604844A1 (en) * 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics, Inc. Cancer-related genes
JP2007051880A (ja) * 2005-08-15 2007-03-01 Tokyo Univ Of Science 膵臓癌の検出方法、膵臓癌の診断キット
NZ593226A (en) * 2006-01-11 2012-10-26 Genomic Health Inc Gene expression markers (efnb2) for colorectal cancer prognosis
WO2008117067A2 (en) * 2007-03-27 2008-10-02 Carl Arne Krister Borrebaeck Protein signature/markers for the detection of adenocarcinoma
US8664358B2 (en) * 2007-06-29 2014-03-04 Vermillion, Inc. Predictive markers for ovarian cancer
EP2271941B1 (en) * 2008-03-07 2012-08-08 OSI Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
GB0815846D0 (en) * 2008-09-01 2008-10-08 Immunovia Ab diagnosis, prognosis and imaging of disease
CN108181457B (zh) * 2009-03-12 2021-03-30 癌症预防和治疗有限公司 鉴定、评估、预防以及治疗肺疾病的方法及试剂盒
WO2011039289A1 (de) * 2009-09-29 2011-04-07 Protagen Ag Markersequenzen für pankreaskrebserkrankungen, pankreaskarzinom und deren verwendung
MY185582A (en) * 2010-01-07 2021-05-24 Malaysian Palm Oil Board Anti-obesity and anti-dyslipidemic effects of oil palm phenolics in preventing atheroslerosis and cardiovascular disease
CN102279264A (zh) * 2010-06-09 2011-12-14 李彬 48种恶性肿瘤标志物抗体芯片的制备方法
CN106011233A (zh) * 2010-08-13 2016-10-12 莫尔豪斯医学院 中风的生物标记
GB201103726D0 (en) * 2011-03-04 2011-04-20 Immunovia Ab Method, array and use thereof
WO2012139628A1 (en) * 2011-04-11 2012-10-18 Lykera Biomed Sa Coding polypurine hairpins for the treatment of cancer

Also Published As

Publication number Publication date
JP6600637B2 (ja) 2019-10-30
EP3069143B1 (en) 2018-10-10
WO2015067969A2 (en) 2015-05-14
EP3069143A2 (en) 2016-09-21
CN105917230A (zh) 2016-08-31
ES2704888T3 (es) 2019-03-20
JP2016537652A (ja) 2016-12-01
GB201319878D0 (en) 2013-12-25
AU2014345484A1 (en) 2016-06-30
AU2014345484B2 (en) 2020-08-27
BR112016010510A2 (pt) 2017-12-05
US20160252513A1 (en) 2016-09-01
WO2015067969A3 (en) 2015-08-06
KR20160085327A (ko) 2016-07-15
KR102240473B1 (ko) 2021-04-15
CA2930211A1 (en) 2015-05-14
CN105917230B (zh) 2020-06-16
US20190128891A1 (en) 2019-05-02
US20220214344A1 (en) 2022-07-07

Similar Documents

Publication Publication Date Title
MX2016006125A (es) Procedimiento, matriz y uso de los mismos.
MX363201B (es) Procedimiento, matriz y uso para determinar la presencia de cancer pancreatico.
MX2018013621A (es) Metodo, matriz y uso de estos.
BR112017010406A2 (pt) processo de realização de teste de alta produtividade de cromatografia líquida de alta eficiência
MX2019008911A (es) Metodos, matrices y usos de estos.
MX2017003790A (es) Detección de secuencias diana por percepción de nanoporos de sondas sintéticas.
MX2017015011A (es) Ensayo a base de celulas para detectar homodimeros anti-cd3.
CL2017001940A1 (es) Dispositivo de medición de la calidad del suelo
WO2017050939A3 (en) Method and array for diagnosing pancreatic cancer in an individual
BR112016019836A2 (pt) método para analisar uma amostra de um sujeito, dispositivo de diagnóstico para utilização no diagnóstico da endometriose, kit, uso de um biomarcador, e, método para aumentar uma resposta de anticorpos em um sujeito
BR112016029583A2 (pt) ?kit ou dispositivo para a detecção de câncer esofágico e método de detecção?
MX2016001719A (es) Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.
MX383381B (es) Métodos y composiciones para detectar proteínas mal plegadas.
BR112016008970A2 (pt) Método de ativação ex vivo e para avaliar ativação plasmática em um indivíduo, ensaio ex vivo para determinar atividade de calicreína plasmática em uma amostra
MX2017010836A (es) Panel biomarcador para la deteccion de cancer.
IL253710B (en) Biomarkers for pancreatic cancer and kits and methods for detecting same
AR089825A1 (es) Metodo para determinar la ubicacion, tamaño y condiciones in situ en un yacimiento de hidrocarburos con ecologia, geoquimica y grupos de biomarcadores
CL2017001212A1 (es) Composiciones, dispositivos y método para pruebas de sensibilidad de síndrome del intestino irritable
UY36223A (es) Dispositivos para ensayos, métodos para realizar ensayos, kits para ensayos y método para fabricar dispositivos para ensayos
MX2016016742A (es) Ceramidas y su uso en el diagnostico de enfermedad cardiovascular (ecv).
MX2018005448A (es) Metodos para la deteccion de apolipoproteinas.
BR112018015965A2 (pt) método para determinação de helicobacter pylori
BR112018000452A2 (pt) medições de função de barreira
HUE065801T2 (hu) Nagy áteresztõképességû sejtalapú szûrés aptamerek vizsgálatához
MX374601B (es) Procedimientos y series para su uso en los mismos.